Regeneron keeps up its co-stimulatory crusade
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
A Prelude to a Lilly duel
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
Pfizer takes on Merck in a new checkpoint
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
